<DOC>
	<DOCNO>NCT00531284</DOCNO>
	<brief_summary>The primary objective Phase 1b/2 study follow : - Phase 1b ( Bolus Infusion ) : To evaluate safety tolerability carfilzomib patient relapse solid tumor patient relapse and/or refractory multiple myeloma patient refractory lymphoma . - Phase 2 ( Bolus ) : To evaluate overall response rate ( ORR ) 4 cycle carfilzomib patient relapse solid tumor .</brief_summary>
	<brief_title>Phase 1b/2 Study Carfilzomib Relapsed Solid Tumors , Multiple Myeloma , Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Disease relate Phase 1 Subjects ( Bolus Infusion ) : Solid Tumor : Histologically confirm advanced solid tumor 1 3 prior treatment regimen At least one site radiographically measurable disease ≥ 2 cm large dimension traditional compute tomography ( CT ) scan technique ≥ 1 cm large dimension spiral CT scanning ( per Response Evaluation Criteria Solid Tumors [ RECIST ] criterion ) ; , Principal Investigator 's opinion , evaluable disease reliably consistently follow , subject may eligible upon approval Medical Monitor Multiple Myeloma ( MM ) : Relapsed and/or refractory multiple myeloma follow 2 prior treatment regimen . Measurable disease indicate one following : Serum Mprotein ≥ 1 g/dL Urine Mprotein ≥ 200 mg/24 hr Serum Free Light Chain : Involved free light chain ( FLC ) level ≥ 10 mg/dL provide serum FLC ratio abnormal Lymphoma : Histologically cytologically confirm lymphoma . Patients must initial diagnosis indolent nonHodgkin lymphoma ( NHL ) ( include follicular , small lymphocytic , lymphoplasmacytoid , marginal zone lymphoma ) , indolent disease transform aggressive subtype , previously describe patient may mantle cell lymphoma . Patients require received prior rituximab ( alone combine treatment ) consider refractory ( define response , progression within 6 month complete therapy ) intolerant continue rituximab . Patients may receive maximum four prior unique chemotherapy regimen , include contraindicate autologous stemcell transplantation ( ASCT ) . For patient enroll expand dose group lymphoma , patient must measurable disease Phase 2 Bolus Subjects : Histologically confirm advanced solid tumor diagnosis : Nonsmall cell lung cancer ( NSCLC ) : Failed least 1 prior platinumbased chemotherapy regimen 3 prior therapy metastatic disease Small cell lung cancer ( SCLC ) : Failed 1 3 prior chemotherapy regimens Ovarian : Failed least 1 prior platinumbased chemotherapy regimen 4 therapy metastatic disease Renal : Failed least 2 prior chemotherapy regimens metastatic disease Other solid tumor type : Failed least 1 prior chemotherapy regimen metastatic relapse disease standard care therapy longer effective exist At least one site radiographically measurable disease ≥ 2 cm large dimension traditional CT scanning technique ≥ 1 cm large dimension spiral CT scanning ( per RECIST criterion ) ; , Principal Investigator 's opinion , evaluable disease reliably consistently follow , subject may eligible upon approval Medical Monitor Demographic Males females ≥ 18 year age Life expectancy 3 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Laboratory Adequate hepatic function , bilirubin 1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) 3 time ULN Absolute neutrophil count ( ANC ) &gt; 1000/mm³ , hemoglobin ≥ 8 gm/dL solid tumor 7.0 gm/dL MM , platelet count ≥ 100,000/mm³ solid tumor ≥ 30,000/mm³ MM . Subjects received platelet transfusion least 1 week prior screen Screening ANC independent granulocyte granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) support least 1 week pegylated GCSF ≥ 2 week Subjects may receive red blood cell ( RBC ) transfusion receive supportive care erythropoietin darbepoetin accordance institutional guideline Calculated measured creatinine clearance ( CrCl ) ≥ 20 mL/minute calculate use formula Cockcroft Gault . Subjects calculate CrCl &lt; 20 mL/min may allow , prior approval Medical Monitor . Ethical/Other Written inform consent accordance federal , local , institutional guideline Female subject childbearing potential must negative serum urine pregnancy test within 3 day first dose agree use dual method contraception study 3 month follow last dose study drug . Postmenopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt requirement . Male subject must use effective barrier method contraception study 3 month follow last dose sexually active female childbearing potential . Disease Related Chemotherapy approve investigational anticancer therapeutic , include steroid therapy , within 3 week prior first dose 6 week antibody therapy Radiation therapy immunotherapy within 3 week prior first dose ( except antibody therapy , 6 week require ) ; localize radiation therapy within 1 week prior first dose Subjects prior brain metastasis permit , must complete treatment evidence active central nervous system ( CNS ) disease least 4 week prior first dose For lymphoma patient ; patient prior stem cell transplant therapy ( autologous SCT within prior 8 week ; allogeneic SCT within prior 16 week ) . Patients prior allogeneic SCT evidence moderatetosevere graftversushost disease ( GVHD ) Evidence CNS lymphoma Participation investigational therapeutic study within 3 week prior first dose Prior treatment carfilzomib Concurrent Conditions Major surgery within 3 week prior first dose Congestive heart failure ( New York Heart Association class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 3 month prior first dose Acute active infection require systemic antibiotic , antiviral , antifungal within 2 week prior first dose Known suspected human immunodeficiency virus ( HIV ) infection subject HIV seropositive Active hepatitis A , B , C infection Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose Subjects pleural effusion require routine thoracentesis ascites require routine paracentesis Subjects risk* require program oral intravenous fluid hydration contraindicate , e.g. , due preexist pulmonary , cardiac , renal impairment High risk Tumor Lysis Syndrome . Ethical / Other Female subject pregnant lactate Any clinically significant psychiatric medical condition opinion Investigator could interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-small cell lung carcinoma</keyword>
	<keyword>Small-cell lung carcinoma</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Renal Cancer</keyword>
	<keyword>Other solid tumor</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>lymphoma</keyword>
</DOC>